• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Van Hauwermeiren Timothy

    11/6/25 8:15:55 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNLI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Van Hauwermeiren Timothy

    (Last) (First) (Middle)
    C/O DENALI THERAPEUTICS INC.
    161 OYSTER POINT BLVD.

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/04/2025
    3. Issuer Name and Ticker or Trading Symbol
    Denali Therapeutics Inc. [ DNLI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24
    No securities are beneficially owned.
    /s/ Tyler Nielsen, by power of attorney 11/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DNLI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNLI

    DatePrice TargetRatingAnalyst
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    2/11/2025$31.00Buy
    Deutsche Bank
    1/7/2025$31.00Outperform
    Robert W. Baird
    1/3/2025Outperform
    William Blair
    12/16/2024$37.00Hold → Buy
    Stifel
    10/10/2024Mkt Perform
    Raymond James
    10/7/2024Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $DNLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Denali Therapeutics upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

    4/10/25 8:28:39 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

    Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously

    3/7/25 8:22:55 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Denali Therapeutics with a new price target

    Deutsche Bank initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $31.00

    2/11/25 7:04:19 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    SEC Filings

    View All

    SEC Form 10-Q filed by Denali Therapeutics Inc.

    10-Q - Denali Therapeutics Inc. (0001714899) (Filer)

    11/6/25 4:05:54 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Denali Therapeutics Inc. (0001714899) (Filer)

    11/6/25 4:03:18 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Denali Therapeutics Inc.

    SCHEDULE 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

    11/5/25 11:30:18 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

    Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on trackDNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIATwo new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer's disease and DNL952 (ETV:GAA) for Pompe diseaseTim Van Hauwermeiren, CEO of argenx, to join Denali's Board of DirectorsCarole Ho, M.D., Chief Medical Officer, departing company; Peter Chin, M.D., assuming role of Acting CMO and Head of DevelopmentDenali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 0

    11/6/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Board and Executive Leadership Updates

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali's Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali's Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in

    11/6/25 4:00:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

    SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The Prescription Drug User Fee Act (PDUFA) target date has been extended from January 5, 2026, to April 5, 2026. The extension follows Denali's submission of updated clinical pharmacology information in response to an information request from the FDA as part of the standard review process and is not related to

    10/13/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Hauwermeiren Timothy was granted 10,632 shares (SEC Form 4)

    4 - Denali Therapeutics Inc. (0001714899) (Issuer)

    11/6/25 8:16:39 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Van Hauwermeiren Timothy

    3 - Denali Therapeutics Inc. (0001714899) (Issuer)

    11/6/25 8:15:55 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Watts Ryan J. gifted 50,000 shares (SEC Form 4)

    4 - Denali Therapeutics Inc. (0001714899) (Issuer)

    9/5/25 4:43:51 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Denali Therapeutics Inc.

    SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

    11/12/24 12:52:28 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

    SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

    11/12/24 9:55:15 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

    SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

    11/8/24 10:52:39 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    Leadership Updates

    Live Leadership Updates

    View All

    Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

    Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on trackDNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIATwo new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer's disease and DNL952 (ETV:GAA) for Pompe diseaseTim Van Hauwermeiren, CEO of argenx, to join Denali's Board of DirectorsCarole Ho, M.D., Chief Medical Officer, departing company; Peter Chin, M.D., assuming role of Acting CMO and Head of DevelopmentDenali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 0

    11/6/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Board and Executive Leadership Updates

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali's Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali's Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in

    11/6/25 4:00:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

    O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar

    4/8/24 8:00:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations